{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:14:53Z","timestamp":1791976493280,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118432","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:05:21Z","timestamp":1764605121000},"page":"118432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer"],"prefix":"10.1016","volume":"303","author":[{"given":"Lin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fushuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118432_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118432_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118432_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"issue":"7689","key":"10.1016\/j.ejmech.2025.118432_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118432_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"suppl_1","key":"10.1016\/j.ejmech.2025.118432_bib6","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-022-01547-3","article-title":"Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR\/Src\/Erk\/SP1 signaling-mediated ERR\u03b1 re-expression","volume":"21","author":"Pan","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12943-023-01780-4","article-title":"Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2\/YBX1\/QSOX1 axis in EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"43","key":"10.1016\/j.ejmech.2025.118432_bib11","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1038\/s41388-025-03572-0","article-title":"TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41392-024-01778-4","article-title":"Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118432_bib13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118432_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.apsb.2021.09.010","article-title":"The generation of PD-L1 and PD-L2 in cancer cells: from nuclear chromatin reorganization to extracellular presentation","volume":"12","author":"Fan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118432_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102561","article-title":"Proteolysis targeting chimeras in non-small cell lung cancer","volume":"117","author":"Hagopian","year":"2023","journal-title":"Cancer Treat Rev."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118432_bib18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: a safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118432_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.37349\/etat.2021.00060","article-title":"Proteolysis-targeting chimeras and their implications in breast cancer","volume":"2","author":"Tecalco-Cruz","year":"2021","journal-title":"Explor Target Antitumor Ther."},{"issue":"40","key":"10.1016\/j.ejmech.2025.118432_bib20","doi-asserted-by":"crossref","first-page":"27382","DOI":"10.1021\/jacs.4c06402","article-title":"ClickRNA-PROTAC for tumor-selective protein degradation and targeted cancer therapy","volume":"146","author":"Teng","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib21","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.2c01909","article-title":"ARE-PROTACs enable Co-degradation of an Nrf2-MafG heterodimer","volume":"66","author":"Ji","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jconrel.2024.10.007","article-title":"Targeted nanoliposomes of oncogenic protein degraders: significant inhibition of tumor in lung-cancer bearing mice","volume":"376","author":"Vartak","year":"2024","journal-title":"J. Contr. Release"},{"issue":"16","key":"10.1016\/j.ejmech.2025.118432_bib23","doi-asserted-by":"crossref","first-page":"13666","DOI":"10.1021\/acs.jmedchem.4c00208","article-title":"Distinct amino acid-based PROTACs target oncogenic kinases for degradation in non-small cell lung cancer (NSCLC)","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126413","article-title":"Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations","volume":"252","author":"Vartak","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118432_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202420977","article-title":"Visualization and quantification of single-base m(6)A methylation","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib26","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41594-025-01537-1","article-title":"Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation","volume":"32","author":"Li","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib27","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118432_bib28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.chembiol.2021.05.010","article-title":"Optical control of targeted protein degradation","volume":"28","author":"Reynders","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118432_bib29","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","article-title":"Strategies for precise modulation of protein degradation","volume":"58","author":"He","year":"2025","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118432_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117352","article-title":"Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4","volume":"90","author":"Cai","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118432_bib31","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.1021\/acs.jmedchem.4c01518","article-title":"Heat shock protein 90 interactome-mediated proteolysis targeting chimera (HIM-PROTAC) degrading glutathione peroxidase 4 to trigger ferroptosis","volume":"67","author":"Dong","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118432_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/1535-7163.MCT-20-0599","article-title":"Targeting STAT3 with proteolysis targeting chimeras and next-generation antisense oligonucleotides","volume":"20","author":"Shiah","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"8071","key":"10.1016\/j.ejmech.2025.118432_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"issue":"7893","key":"10.1016\/j.ejmech.2025.118432_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib35","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1038\/s41467-022-34562-5","article-title":"Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers","volume":"13","author":"Cantley","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118432_bib36","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ccell.2024.06.006","article-title":"Targeting the mSWI\/SNF complex in POU2F-POU2AF transcription factor-driven malignancies","volume":"42","author":"He","year":"2024","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118432_bib37","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1039\/D5CS00479A","article-title":"Chemical-assisted analysis of epigenetic modifications","volume":"54","author":"Teng","year":"2025","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118432_bib38","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1039\/D2NP00038E","article-title":"Natural product-based PROteolysis TArgeting chimeras (PROTACs)","volume":"39","author":"Liu","year":"2022","journal-title":"Nat. Prod. Rep."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118432_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.575","article-title":"PROteolysis-Targeting chimeras (PROTACs) in leukemia: overview and future perspectives","volume":"5","author":"Vicente","year":"2020","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"8002","key":"10.1016\/j.ejmech.2025.118432_bib41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","volume":"627","author":"Hsia","year":"2024","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib42","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1039\/D2CS00148A","article-title":"E3 ligase ligand chemistries: from building blocks to protein degraders","volume":"51","author":"Sosi\u010d","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118432_bib43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118432_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"51","key":"10.1016\/j.ejmech.2025.118432_bib45","doi-asserted-by":"crossref","first-page":"26663","DOI":"10.1002\/anie.202108848","article-title":"Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs","volume":"60","author":"Min","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118432_bib46","article-title":"Regulated induced proximity targeting chimeras (RIPTACs): a novel heterobifunctional small molecule therapeutic strategy for killing cancer cells selectively","volume":"31","author":"Raina","year":"2023","journal-title":"bioRxiv"},{"issue":"19","key":"10.1016\/j.ejmech.2025.118432_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911068","article-title":"MDM2-Based proteolysis-targeting chimeras (PROTACs): an innovative drug strategy for cancer treatment","volume":"23","author":"Vicente","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118432_bib48","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-Inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118432_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.34133\/cbsystems.0067","article-title":"The autonomous pipeline navigation of a cockroach bio-robot with enhanced walking stimuli","volume":"4","author":"Ma","year":"2023","journal-title":"Cyborg Bionic Syst"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118432_bib50","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118432_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202414146","article-title":"Self-assembled peptide-derived proteolysis-targeting chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy","volume":"64","author":"Moon","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118432_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202421713","article-title":"In vivo self-assembly of PROTACs by bioorthogonal chemistry for precision cancer therapy","volume":"64","author":"Xie","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118432_bib53","doi-asserted-by":"crossref","first-page":"mr3","DOI":"10.1091\/mbc.E24-08-0342","article-title":"HaloPROTAC3 treatment activates the unfolded protein response of the endoplasmic reticulum in nonengineered mammalian cell lines","volume":"36","author":"Anisimova","year":"2025","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmech.2025.118432_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.34133\/cbsystems.0015","article-title":"Ultrafast miniature robotic swimmers with upstream motility","volume":"4","author":"Wang","year":"2023","journal-title":"Cyborg Bionic Syst"},{"issue":"6715","key":"10.1016\/j.ejmech.2025.118432_bib55","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118432_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212142","article-title":"Small-molecule inhibitors and degraders targeting KRAS-driven cancers","volume":"22","author":"Hyun","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118432_bib57","doi-asserted-by":"crossref","first-page":"14237","DOI":"10.1021\/acs.jmedchem.2c01454","article-title":"Novel allosteric inhibitor-derived AKT proteolysis targeting chimeras (PROTACs) enable potent and selective AKT degradation in KRAS\/BRAF mutant cells","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8051","key":"10.1016\/j.ejmech.2025.118432_bib58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","volume":"638","author":"Zhang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118432_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114533","article-title":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","volume":"239","author":"Hong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118432_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2024.2355258","article-title":"Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023","volume":"34","author":"Lee","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib61","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1021\/acs.jmedchem.4c02577","article-title":"Discovery of novel, potent, and orally bioavailable SMARCA2 proteolysis-targeting chimeras with synergistic antitumor activity in combination with Kirsten rat sarcoma viral oncogene homologue G12C inhibitors","volume":"68","author":"Kotagiri","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol Biomed"},{"key":"10.1016\/j.ejmech.2025.118432_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2025.118432_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.34133\/cbsystems.0009","article-title":"Field-controlled microrobots fabricated by photopolymerization","volume":"4","author":"Liang","year":"2023","journal-title":"Cyborg Bionic Syst"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118432_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"issue":"30","key":"10.1016\/j.ejmech.2025.118432_bib67","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1021\/jacs.3c04109","article-title":"Self-assembled Nano-PROTAC enables near-infrared photodynamic proteolysis for cancer therapy","volume":"145","author":"Wang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib68","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118432_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115128","article-title":"Degradation of histone deacetylase 6 alleviates ROS-mediated apoptosis in renal ischemia-reperfusion injury","volume":"165","author":"Xia","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54854-2","article-title":"MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition","volume":"15","author":"Tong","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib71","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118432_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113719","article-title":"Advancements in delivery systems for proteolysis-targeting chimeras (PROTACs): overcoming challenges and expanding biomedical applications","volume":"382","author":"Yu","year":"2025","journal-title":"J. Contr. Release"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118432_bib73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1166\/jbn.2018.2538","article-title":"Biodegradable interlayer-crosslinked polymer micelles with reduction sensitivity for non-small cell lung cancer therapy","volume":"14","author":"Wang","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"issue":"43","key":"10.1016\/j.ejmech.2025.118432_bib74","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118432_bib75","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-Targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118432_bib76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118432_bib77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118432_bib78","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118432_bib81","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/acs.accounts.5c00158","article-title":"Primary amine-based photoclick chemistry: from concept to diverse applications in chemical biology and medicinal chemistry","volume":"58","author":"Hu","year":"2025","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118432_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115082","article-title":"Discovery of the GSH responsive \"Y-PROTACs\" targeting ALK and CDK4\/6 as a potential treatment for cancer","volume":"248","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106793","article-title":"Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors","volume":"140","author":"Fan","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib84","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1021\/jacs.4c18398","article-title":"A dual-targeted molecule for disease-activatable proteolysis targeting chimeras and targeted radionuclide therapy of cancer","volume":"147","author":"Zhang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib85","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12951-024-02967-7","article-title":"Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy","volume":"22","author":"Guan","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118432_bib86","doi-asserted-by":"crossref","first-page":"16828","DOI":"10.1021\/acs.jmedchem.3c01539","article-title":"Enhanced tumor targeting and penetration of proteolysis-targeting chimeras through iRGD peptide conjugation: a strategy for precise protein degradation in breast cancer","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13148-021-01037-1","article-title":"Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells","volume":"13","author":"Dominici","year":"2021","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2025.118432_bib88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2016.12.012","article-title":"Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells","volume":"104","author":"Sesumi","year":"2017","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.ejmech.2025.118432_bib89","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118432_bib90","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","article-title":"A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death","volume":"57","author":"Mannion","year":"2024","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118432_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160606","article-title":"Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer","volume":"7","author":"Jin","year":"2022","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118432_bib92","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41401-024-01312-w","article-title":"A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects","volume":"45","author":"Xu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118432_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.151001","article-title":"Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation","volume":"740","author":"Kumar","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118432_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118352","article-title":"Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines","volume":"189","author":"Arenas-Moreira","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"26","key":"10.1016\/j.ejmech.2025.118432_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300871","article-title":"Exploiting cancer vulnerabilities by blocking of the DHODH and GPX4 pathways: a multifunctional Bodipy\/PROTAC nanoplatform for the efficient synergistic ferroptosis therapy","volume":"12","author":"Yao","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2025.118432_bib96","article-title":"Liposomal STAT3-Degrading PROTAC prodrugs promote anti-hepatocellular carcinoma immunity via chemically reprogramming cancer stem cells","author":"Wang","year":"2024","journal-title":"Nano Lett."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118432_bib97","doi-asserted-by":"crossref","first-page":"14155","DOI":"10.1021\/jacs.3c05159","article-title":"Bioorthogonal PROTAC prodrugs enabled by On-Target activation","volume":"145","author":"Chang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118432_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400109","article-title":"Folate-PEG-PROTAC micelles for enhancing tumor-specific targeting proteolysis in vivo","volume":"13","author":"Ma","year":"2024","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2025.118432_bib100","article-title":"Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced T cell-mediated tumor immunotherapy","volume":"10","author":"Xiang","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.ejmech.2025.118432_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112657","article-title":"Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders","volume":"204","author":"Tang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118432_bib102","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41417-022-00472-3","article-title":"Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K\/S6, Bim and Mcl-1","volume":"29","author":"Deng","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118432_bib103","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112377","article-title":"Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1","volume":"199","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118432_bib105","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"50","key":"10.1016\/j.ejmech.2025.118432_bib106","doi-asserted-by":"crossref","first-page":"eabq2216","DOI":"10.1126\/sciadv.abq2216","article-title":"Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras","volume":"8","author":"Do","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118432_bib107","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational design for nitroreductase (NTR)-responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107943","article-title":"Discovery of potent hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) degraders by proteolysis targeting chimera (PROTAC)","volume":"153","author":"Li","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106590","article-title":"Discovery of estrogen receptor \u03b1 targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment","volume":"137","author":"Xie","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118432_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411869","article-title":"Self-oxygenating PROTAC microneedle for spatiotemporally-confined protein degradation and enhanced glioblastoma therapy","volume":"37","author":"Jiang","year":"2025","journal-title":"Adv. Mater."},{"issue":"28","key":"10.1016\/j.ejmech.2025.118432_bib111","doi-asserted-by":"crossref","first-page":"25830","DOI":"10.1021\/acsnano.5c04580","article-title":"Oxygen-generating transdermal nanoplatform codelivering BRD4 proteolysis-targeting Chimera\/Verteporfin\/CaO(2) synergistically remodels immunosuppressive melanoma microenvironment to potentiate combination immunotherapy","volume":"19","author":"Wei","year":"2025","journal-title":"ACS Nano"},{"issue":"38","key":"10.1016\/j.ejmech.2025.118432_bib112","article-title":"Lactylated apolipoprotein C-II induces immunotherapy resistance by promoting extracellular lipolysis","volume":"11","author":"Chen","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118432_bib113","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2967\/jnumed.114.145490","article-title":"Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas","volume":"55","author":"Zhou","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.118432_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2025.113015","article-title":"Lysosome-targeted theranostics: integration of real-time fluorescence imaging and controlled drug delivery via Zn(II)-Schiff base complexes","volume":"272","author":"Lai","year":"2025","journal-title":"J. Inorg. Biochem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118432_bib115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic heterogeneity in human lung tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118432_bib116","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1148\/rg.324105181","article-title":"Radiofrequency ablation of lung tumors: imaging features of the postablation zone","volume":"32","author":"Abtin","year":"2012","journal-title":"Radiographics"},{"key":"10.1016\/j.ejmech.2025.118432_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117237","article-title":"Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands","volume":"82","author":"Cheng","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"95","key":"10.1016\/j.ejmech.2025.118432_bib118","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118432_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216022","article-title":"SMARCA4: current status and future perspectives in non-small-cell lung cancer","volume":"554","author":"Tian","year":"2023","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118432_bib120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jtho.2021.03.024","article-title":"SMARCA4 and other SWItch\/Sucrose NonFermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition","volume":"16","author":"Alessi","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"30","key":"10.1016\/j.ejmech.2025.118432_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202505669","article-title":"Functional dendrimer nanogels for DNA delivery and gene therapy of tumors","volume":"64","author":"Li","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118432_bib122","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.3c01781","article-title":"PROTACs targeting BRM (SMARCA2) afford selective in vivo degradation over BRG1 (SMARCA4) and are active in BRG1 mutant xenograft tumor models","volume":"67","author":"Berlin","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118432_bib123","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118432_bib124","first-page":"762","article-title":"Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer","volume":"22","author":"Khan","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"7968","key":"10.1016\/j.ejmech.2025.118432_bib125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118432_bib126","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10555-021-09990-2","article-title":"Targeting KRAS in pancreatic cancer: new drugs on the horizon","volume":"40","author":"Bannoura","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118432_bib127","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acsmedchemlett.5c00111","article-title":"Targeting oncogenic pathways: advances in KRAS, CDK, EGFR, and PROTAC-based therapies","volume":"16","author":"Kargbo","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118432_bib128","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/curroncol31040150","article-title":"KRAS: biology, inhibition, and mechanisms of inhibitor resistance","volume":"31","author":"Ash","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2025.118432_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114838","article-title":"A bibliometric analysis of PROTAC from 2001 to 2021","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118432_bib130","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2025.118432_bib131","doi-asserted-by":"crossref","first-page":"673","DOI":"10.34133\/research.0673","article-title":"Isobutyrate confers resistance to inflammatory bowel disease through host-microbiota interactions in pigs","volume":"8","author":"Fang","year":"2025","journal-title":"Research"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","article-title":"MDM2-Recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53","volume":"79","author":"Hines","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1021\/acsmedchemlett.3c00449","article-title":"MDM2 antagonist idasanutlin reduces HDAC1\/2 abundance and corepressor partners but not HDAC3","volume":"15","author":"Smalley","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118432_bib134","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2024.11.076","article-title":"PROTAC delivery in tumor immunotherapy: where are we and where are we going?","volume":"378","author":"Li","year":"2025","journal-title":"J. Contr. Release"},{"issue":"32","key":"10.1016\/j.ejmech.2025.118432_bib135","article-title":"Systemic administration of neurotransmitter-derived Lipidoids-PROTACs-DNA nanocomplex promotes Tau clearance and cognitive recovery for Alzheimer's disease therapy","volume":"13","author":"Gong","year":"2024","journal-title":"Adv. Healthcare Mater."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib136","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118432_bib137","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.tips.2024.10.006","article-title":"Development of PROTACs using computational approaches","volume":"45","author":"Ge","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"6668","key":"10.1016\/j.ejmech.2025.118432_bib138","doi-asserted-by":"crossref","first-page":"eadf6249","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.ejmech.2025.118432_bib139","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1021\/acs.jmedchem.2c00302","article-title":"Enriching proteolysis targeting chimeras with a second modality: when two are better than one","volume":"65","author":"Salerno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118432_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114455","article-title":"Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686","volume":"238","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118432_bib141","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118432_bib142","doi-asserted-by":"crossref","first-page":"20943","DOI":"10.1021\/acsami.5c01103","article-title":"Targeted degradation of EGFR mutations via self-delivery Nano-PROTACs for boosting tumor synergistic immunotherapy","volume":"17","author":"Wang","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"29","key":"10.1016\/j.ejmech.2025.118432_bib143","article-title":"Versatile Nano-PROTAC-Induced epigenetic reader degradation for efficient lung cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118432_bib144","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2542357","article-title":"FDA-approved kinase inhibitors in PROTAC design, development and synthesis","volume":"40","author":"Kossakowski","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"Pt 1","key":"10.1016\/j.ejmech.2025.118432_bib145","article-title":"Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment","volume":"275","author":"Fan","year":"2024","journal-title":"Int. J. Biol. Macromol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:53:44Z","timestamp":1781326424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":145,"alternative-id":["S0223523425011973"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118432","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118432"}}